Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suvratoxumab - MedImmune

Next Previous
Drug Profile

Suvratoxumab - MedImmune

Alternative Names: MEDI-4893

Latest Information Update: 24 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosynexus; GlaxoSmithKline; Regeneron Pharmaceuticals
  • Developer MedImmune
  • Class Anti-infectives; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia

Most Recent Events

  • 02 Oct 2018 MedImmune completes the SAATELLITE phase II trial in Nosocomial pneumonia (Prevention) in Portugal, United Kingdom, Belgium, Czech Republic, France, Germany, Greece, Hungary, Spain and Switzerland (IV) (NCT02296320)
  • 07 May 2018 Phase-II clinical trials in Nosocomial pneumonia (Prevention) in USA (IV) before May 2018 (NCT02296320)
  • 21 Apr 2018 Pharmacodynamics data from preclinical trials in Nosocomial pneumonia (Prevention) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top